Top Analyst Upgrades and Downgrades: Alcoa, Cemex, Comerica, Facebook, GM, Incyte, Proofpoint, Regeneron and More

Stocks were hammered on Friday for the end of a volatile week, but stock indices were indicated higher on Monday, with a 150-point rise in the Dow Jones industrial average and 13-point rise in the S&P 500. The bull market is now over nine years old, and the trend of buying pullbacks has become much more vulnerable to sellers and volatility trades. The climate has made it more difficult for investors to decide how they want their assets positioned for the rest of 2018 and beyond.

24/7 Wall St. reviews dozens of analyst research reports each day of the week. Our goal is to find new ideas for investors and traders alike. Some analyst reports cover stocks to buy, and some cover stocks to sell or to avoid.

Additional color and commentary has been added on most of the daily analyst reports. The consensus analyst price targets and other valuation metrics are from the Thomson Reuters sell-side research service.

These were the top analyst upgrades, downgrades and other research calls from Monday, April 9, 2018.

Alcoa Corp. (NYSE: AA) was maintained as Buy at Citigroup, but the firm lowered its price target to $57 from $65. The stock closed up 0.9% at $48.05 despite the sell-off, and its shares were indicated up just over 3% at $49.50 on Monday.

AMC Entertainment Holdings Inc. (NYSE: AMC) was reiterated as Outperform with a $25 price target (versus a $16.45 prior close) at Wedbush Securities. The firm saw a strong first quarter and is calling for a heavy slate of summer movies.

Arcus Biosciences Inc. (NASDAQ: RCUS) was started with an Outperform rating and assigned a $21 target price (versus a $14.34 close) at Leerink. Shares traded up 2.3% at $14.67 on Monday’s early indications.

CEMEX SAB de CV (NYSE: CX) was raised to Buy from Neutral and the price objective was raised to $8.50 from $8.00 (versus $6.87 close) at Merrill Lynch.

Cinemark Holdings Inc. (NYSE: CNK) was reiterated as Outperform with a $47 price target (versus a $39.13 close) at Wedbush. The firm saw a better-than-expected first quarter and is calling for a heavy slate of summer movies.

Clovis Oncology Inc. (NASDAQ: CLVS) was reiterated as Buy with a $90 price objective (versus a $55.52 close) at Merrill Lynch, with the firm noting that Rubraca received a full label as a second line of defense maintenance setting for ovarian cancer.

Comerica Inc. (NYSE: CMA) was raised to Outperform from Neutral and the price target was raised to $111 from $103 (versus a $94.92 close) at Wedbush. The firm sees coming drivers to earnings from margin expansion, potential resumption of loan growth and above-average capital returns.

Facebook Inc. (NASDAQ: FB) was maintained as Buy at Jefferies, but the firm lowered its price target to $215 from $230. Facebook has a 52-week range of $138.81 to $195.32, and the consensus target price was last seen at $218.22.

Follow @Jonogg on Twitter to receive the daily analyst calls and other market research calls directly on your feed.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.